Skip to main content

Advertisement

Figure 4 | Clinical Epigenetics

Figure 4

From: Leucine alters hepatic glucose/lipid homeostasis via the myostatin-AMP-activated protein kinase pathway - potential implications for nonalcoholic fatty liver disease

Figure 4

Effects of myostatin (MSTN) on AMP-activated protein kinase (AMPK) activity and glucose /lipid sensing in leucine- treated HepG2 cells. (A) Glucose uptake is repressed in MSTN-suppressed cells. MSTN knock-down efficiency using siRNA (B) The leucine- induced AMPK signaling pathway was suppressed following MSTN suppression. (C) mRNA levels of leucine-sensitive genes in the presence and absence of MSTN. Values are presented as the mean ± SEM. Statistical significance relative to untreated control, *P <0.05, **P <0.01 (n =3).

Back to article page